Byong Chul Yoo

Dr. Byong Chul Yoo


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KKKyung-hee Kim
Kyung-hee Kim
MYMaro Yoo
Maro Yoo
MCMin Yeong Choi
Min Yeong Choi
BYByong Chul Yoo
Byong Chul Yoo
Metabolomics and lipidomics enable comprehensive profiling of metabolic states across diverse diseases and have generated a vast number of candidate biomarkers. Despite this progress, only a small fraction of metabolite-based biomarkers have achieved durable clinical translation. While this gap is often attributed to biological complexity or limited cohort size, increasing evidence suggests that failure more commonly reflects systematic misalignment between analytical measurement, biological interpretation, and clinical decision-making requirements. In this review, we argue that metabolites are not intrinsically unreliable biomarkers but are frequently overinterpreted as disease-specific indicators despite being highly context-dependent reporters of physiological state. We synthesize recurrent failure modes across the translational pipeline—including pre-analytical instability, ionization bias and semi-quantitative measurement, structural and annotation ambiguity, statistical overfitting, loss of disease specificity under systemic stress, and cohort-dependent performance collapse. Building on these insights, we propose a structured roadmap for the clinical translation of metabolite and lipid biomarkers. Rather than emphasizing further discovery, this framework prioritizes decision-oriented eligibility criteria encompassing pre-analytical robustness, analytical validity, molecular definition, biological interpretability, validation under real-world heterogeneity, and alignment with clinical utility and regulatory expectations. By reframing metabolic biomarkers as context-sensitive measurements embedded within clinical decision systems, this review provides practical guidance for investigators, clinicians, and regulators seeking to translate metabolomics and lipidomics into reliable tools for clinical practice.

Verified
Journal Article
Open access
PDF file
KKKyung-hee Kim
Kyung-hee Kim
BYByong Chul Yoo
Byong Chul Yoo
Liquid biopsy has become an integral component of precision oncology, with circulating tumor DNA serving as the dominant analyte for genomic profiling and disease monitoring. However, DNA-based approaches are intrinsically limited in their ability to capture dynamic cellular states, functional adaptation, and tumor–host interactions. Circulating RNA has emerged as a complementary class of liquid biopsy biomarkers that reflects active transcriptional programs and systemic biological responses. In this review, we conceptualize circulating RNA as a liquid transcriptome and propose a structured classification framework based on physical carriers, RNA biotypes, and layers of biological interpretation. We describe how circulating RNA signals encode tissue-of-origin information, cell-state dynamics, and host immune responses, thereby enabling system-level insight into cancer biology beyond mutation-centric analyses. Recent large-scale profiling efforts and advances in extracellular RNA characterization further support the biological relevance and analytical feasibility of circulating RNA across diverse biofluids. We discuss emerging applications of circulating RNA across the cancer continuum, including early cancer detection and multi-cancer screening, tissue-of-origin inference, longitudinal monitoring of treatment response, detection of adaptive resistance, and immunotherapy stratification. In parallel, we critically examine key technical, analytical, and computational challenges that currently limit reproducibility and clinical translation, emphasizing the importance of standardized workflows, transparent reporting, and multi-center validation. Finally, we outline future directions for integrating circulating RNA with genomic and proteomic biomarkers, supported by advances in artificial intelligence and machine learning. Collectively, this review positions circulating RNA as a functionally informative and clinically promising component of next-generation liquid biopsy strategies in oncology.

Verified
Journal Article
Open access
PDF file
KKKyung-hee Kim
Kyung-hee Kim
BYByong Chul Yoo
Byong Chul Yoo
Biological membranes are dynamic, information-rich platforms whose structural and functional properties are dictated by lipid composition rather than acting as passive barriers. Recent advances in lipidomics have revealed that variations in lipid headgroups, acyl-chain length and saturation, sn-positional architecture, and oxidative modifications profoundly influence membrane mechanics, lateral organization, and protein–lipid interactions. These features collectively regulate fundamental cellular processes, including signaling, trafficking, curvature generation, and transbilayer asymmetry. In parallel, a wide range of pathological conditions—including cancer, metabolic disorders, neurodegeneration, and inflammatory diseases—are increasingly associated with coordinated lipid remodeling that reshapes membrane material properties and electrostatic landscapes. In this review, we integrate biophysical principles with lipidomics-based evidence to elucidate how lipid chemical diversity translates into membrane-level behavior. We discuss the roles of major membrane lipid classes, the functional consequences of acyl-chain and sn-positional remodeling, and the biological significance of lipid asymmetry and lateral heterogeneity. Particular attention is given to disease-associated lipid reprogramming and extracellular vesicle lipidomes as functional extensions of cellular membranes. Finally, we examine key analytical barriers in modern lipidomics and outline strategies required to connect lipid structural information with biological function. Together, this framework highlights membrane lipid architecture as a central determinant of cellular physiology and a promising axis for mechanistic insight and translational biomarker discovery.

28 April 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
WCWooram Choi
Wooram Choi
JCJeong Hun Cho
Jeong Hun Cho
SPSang Hee Park
Sang Hee Park
DKDong Seon Kim
Dong Seon Kim
HLHwa Pyoung Lee
Hwa Pyoung Lee
Jae Youl ChoJae Youl Cho
Jae Youl Cho
Introduction: Plant-derived exosome-like nanoparticles (PDENs) have emerged as bioactive nanostructures capable of transferring molecular cargos across species; however, their mechanistic roles in mammalian stress-responsive signaling remain incompletely defined. In this study, we investigated the effects of green tea ( Camellia sinensis (L.) Kuntze [Theaceae])–derived exosome-like nanoparticles (GtDENs) on oxidative stress–induced cellular dysfunction in human keratinocytes. Methods: To do this, we employed MTT assay, immunoblotting analysis, real-time PCR method, SA-beta-gal assay, flowcytometry, and molecular docking model. Results and Discussion: GtDENs exhibited no detectable cytotoxicity and significantly attenuated hydrogen peroxide– and UVB-induced reactive oxygen species (ROS) accumulation and cell death. GtDENs suppressed oxidative stress–associated cellular senescence and apoptotic gene expression, including MMP3, p21, and caspases. Mechanistically, GtDENs preferentially reduced phosphorylation of p38 MAPK and downstream c-Fos activation under oxidative stress conditions, while ERK and JNK signaling remained largely unaffected. Functional analyses, including p38 overexpression and pharmacological inhibition experiments, support the involvement of p38 MAPK signaling in mediating GtDEN activity. Phytochemical profiling identified caffeine as the predominant small-molecule component within GtDENs. Molecular docking and cellular thermal shift assays suggest potential interaction between caffeine and p38 MAPK, although direct biochemical binding validation was not performed. Exploratory small RNA profiling further indicated the presence of regulatory RNA species associated with stress-responsive pathways. Collectively, these findings indicate that GtDENs modulate oxidative stress–responsive signaling, with p38 MAPK emerging as a key signaling axis involved in this response.

Verified
Journal Article
Open access
PDF file
KKKyung-hee Kim
Kyung-hee Kim
BYByong Chul Yoo
Byong Chul Yoo
Glycosylation is one of the most prevalent post-translational modifications of membrane proteins and plays a central role in regulating their structure and function. Unlike many existing reviews that address glycosylation in a system-wide context, this review focuses specifically on membrane proteins and examines how glycosylation shapes their functional behavior and clinical relevance. Because membrane proteins are exposed to the extracellular environment, glycans on their surface directly influence protein folding, receptor organization, and interactions with ligands and immune components. These diverse effects can be understood within a common mechanistic framework in which glycosylation modulates protein conformation, receptor clustering, and membrane organization, thereby altering signaling, adhesion, transport, and immune recognition. We discuss how N-linked and O-linked glycosylation regulate major classes of membrane proteins across these processes. Particular attention is given to disease-associated alterations in glycosylation, especially in cancer, immune and inflammatory disorders, and metabolic disease. For instance, glycosylation-dependent stabilization of PD-L1 and modulation of receptor signaling, such as EGFR, illustrate how glycan modifications contribute to immune evasion and therapeutic response. We further consider the clinical implications of membrane protein glycosylation, including its roles in biomarker development and as a potential target for therapeutic intervention. Advances in glycoproteomic technologies have enabled increasingly detailed characterization of site-specific glycosylation, although significant analytical challenges remain, particularly for membrane proteins. Overall, this review highlights membrane protein glycosylation as a dynamic regulatory layer that links molecular mechanisms to functional outcomes and clinical applications.

Verified
Journal Article
Open access
PDF file
KKKyung-hee Kim
Kyung-hee Kim
BYByong Chul Yoo
Byong Chul Yoo
Multi-omics technologies enable parallel quantification of proteomic and metabolomic layers, yet enzyme abundance often shows weak or nonlinear correspondence under diverse biological conditions. This apparent discordance has been attributed to both technical limitations—such as dynamic range compression in LC-MS/MS, metabolite derivatization artifacts, and missing values in proteomic measurements—as well as intrinsic biological properties of metabolic network architecture. While technical factors contribute to cross-omic mismatch, accumulating evidence suggests that constraint-driven network behavior plays a major role in shaping this decoupling. Enzyme abundance constrains catalytic capacity; however, realized flux is selected within this capacity under distributed flux control, as formalized by flux control coefficients in metabolic control analysis, and is further modulated by enzyme kinetics (e.g., km and Vmax), post-translational modifications, substrate availability, and thermodynamic constraints. Metabolite pools, in turn, reflect the physicochemical state of the system, while specific metabolites can also act as regulatory effectors that modulate enzymatic activity and cellular signaling. Because metabolic networks are underdetermined, multiple flux configurations can satisfy identical protein abundance and metabolite concentration data. Static cross-layer correlation is therefore insufficient for mechanistic inference. We synthesize biological mechanisms—including post-translational regulation, allostery, thermodynamic buffering, spatial compartmentalization, feedback amplification, and redox gating—that weaken linear abundance–metabolite expectations. We further outline a constraint-based interpretation framework in which proteomics imposes capacity bounds, metabolomics informs reaction directionality and metabolite pool constraints, and flux-informed approaches reduce solution degeneracy by providing additional information on pathway activity. Moving beyond correlation requires integrating perturbation, temporal resolution, and constraint-aware modeling. Proteome–metabolome discordance should therefore be interpreted not as inconsistency, but as indicative of constraint-driven state selection within high-dimensional biochemical systems.